About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT00573469

Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease

The purpose of this study is to determine whether treatment with D9421-C for 8 weeks in Japanese patients with mild to moderate active Crohn's disease will improve their symptoms of Crohn's disease an...

Lead sponsor: AstraZeneca•22 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

AstraZeneca

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Female or male aged ≥ 18 and ≤ 65 years
•Diagnosis of Crohn's Disease

Exclusion Criteria

•Having ileostomy or pouch and/or colostomy
•Having previous gastric surgery
•Having a known or suspected systemic infection

Related studies

RECRUITINGPhase 3

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931 · Crohn's Disease

RECRUITINGPhase 3

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

NCT06100289 · Ulcerative Colitis, Crohn's Disease

RECRUITINGPhase 3

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more

RECRUITINGPhase 4

Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

NCT06180382 · Crohn's Disease

Real-World Study of IL-23 Inhibitors in Active Crohn's Disease

NCT07545317 · Crohn's Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 12, 2012Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment75

Start dateOct 2006

Last updatedJul 12, 2012

Condition

Crohn's Disease

Locations shown

Research Site

Nagoya, Aichi-ken

Research Site

Sakura, Chiba

Research Site

Chikushino-shi, Fukuoka

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 12, 2012Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions